Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
AssigneeEirgen Pharma Ltd.
InventorsP. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
Life of this patent
Estimating the term…
Abstract
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
Claims24
A method of treating or preventing iatrogenic hypocalcemia and/or secondary hyperparathyroidism in a patient treated with an agent that increases the risk of hypocalcemia, comprising administering to the patient a formulation comprising a 25-hydroxyvitamin D compound.
A method of lowering elevated serum parathyroid hormone levels and/or stabilizing serum calcium levels in a patient having a bone metastasis and treated with an agent that increases the risk of hypocalcemia comprising administering to the patient an effective amount of 25-hydroxyvitamin D.
A method of treating a patient at risk for hypocalcemia wherein the patient is treated with an agent that increases the risk of hypocalcemia, comprising administering to the patient 25-hydroxyvitamin D in an amount effective to restore and maintain blood 25(OH)D levels to at least 30 ng/mL.
Dependencies are inferred from the claim text.